Researchers have explored the evolution of the genetic change that causes chronic myeloid leukaemia and show its ability to drive the disease.

Enliven Therapeutics is a clinical-stage concern that has two candidates in its pipeline targeting oncology indications.

However, despite its well-understood role in CML, little is known about the evolution of this fusion gene, the rate at which cells with BCR::ABL1 start to multiply, and how this contributes to ...

Figure 2: BCR-ABL contributes to differentiation arrest ... It seems likely that microarray gene-expression profiling will continue to identify many candidate genes. The next challenge is ...

Cite this: Abl Tyrosine Kinase Inhibitors for Overriding Bcr-Abl/T315I: From the Second to Third Generation - Medscape - Sep 01, 2008.

In those with CML, part of the ABL1 gene from chromosome 9 is fused with the BCR gene from chromosome 22. This creates an abnormal fusion gene called BCR::ABL1 on chromosome 22, also known as the ...

However, despite its well-understood role in CML, little is known about the evolution of this fusion gene, the rate at which cells with BCR::ABL1 start to multiply, and how this contributes to ...

However, despite its well-understood role in CML, little is known about the evolution of this fusion gene, the rate at which cells with BCR::ABL1 start to multiply, and how this contributes to ...